Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 5/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | BLM | P54132 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | RGS12 | O14924 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129381 | 0.92 | HMGCR (0.85) | HMGCRNR1I2MEN1CYP3A4MAPT | |
| SCHEMBL7137096 | 0.91 | HMGCR (0.83) | HMGCRNR1I2MEN1CYP3A4MAPT | |
| SCHEMBL7139090 | 0.83 | HMGCR (0.71) | HMGCRNR1I2CYP1A2CYP2C9GABBR2 | |
| SCHEMBL7141651 | 0.83 | HMGCR (0.71) | HMGCRNR1I2MEN1CYP3A4MAPT | |
| SCHEMBL678403 | 0.79 | HMGCR (1.00) | HMGCRNR1I2MEN1CYP3A4MAPT | |
| SCHEMBL7134489 | 0.79 | HMGCR (0.65) | HMGCRNR1I2CYP3A4CYP1A2LMNA | |
| SCHEMBL7132005 | 0.78 | HMGCR (0.63) | HMGCRNR1I2MEN1CYP3A4MAPT | |
| SCHEMBL14206895 | 0.78 | HMGCR (0.63) | HMGCRNR1I2MEN1CYP3A4MAPT | |
| SCHEMBL7083575 | 0.78 | HMGCR (0.63) | HMGCRNR1I2MEN1MAPTKMT2A | |
| SCHEMBL7079812 | 0.78 | HMGCR (0.63) | HMGCRNR1I2MEN1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326618-A2 | USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES | Ilex Oncology Research S.A. (CH) | 2003-07-16 | — | — | EP | claimed |
| WO-2002011704-A2 | USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES | SYMPHAR S.A. (CH) | 2002-02-14 | — | — | WO | claimed |
| EP-0845991-B1 | USE OF PHENOL SUBSTITUTED DIPHOSPHONATES AS ANTINEOPLASTIC AGENTS | SYMPHAR SA (CH) | 2002-02-06 | — | — | EP | claimed |
| EP-0339237-B1 | PHENOL SUBSTITUTED GEM-DIPHOSPHONATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYMPHAR S.A. (CH) | 1992-12-30 | — | — | EP | claimed |
| US-5128331-A | Gen-diphosphonates | SYMPHAR S.A. (CH) | 1992-07-07 | — | — | US | claimed |
| US-8529877-B2 | Benzylidene compounds comprising phosphono-groups | BASF SE (DE) | 2013-09-10 | — | — | US | disclosed |
| US-8529877-B2 | Benzylidene compounds comprising phosphono-groups | BASF SE (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20110212039-A1 | BENZYLIDENE COMPOUNDS COMPRISING PHOSPHONO-GROUPS | BASF SE (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212039-A1 | BENZYLIDENE COMPOUNDS COMPRISING PHOSPHONO-GROUPS | BASF SE (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2010054966-A2 | BENZYLIDENE COMPOUNDS COMPRISING PHOSPHONO-GROUPS | BASF SE (DE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212039-A1 | BENZYLIDENE COMPOUNDS COMPRISING PHOSPHONO-GROUPS | NR1H2, ESRRA, NR1H3 | HMGCR 1411/4885NR1I2 67/4885MEN1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.